COVID: New modeler vaccine for South African variants

Moderna states that a version of the COVID-19 vaccine specifically aimed at combating South African viral variants will undergo clinical trials.

Cambridge, Massachusetts — Modana Announced on Wednesday it brewed its experimental dose COVID-19 vaccine This is a better match for the mutated version of the virus and is ready for testing to see how the update works.

Health officials say first generation COVID-19 (new coronavirus infection) (# If there is no character limit, add parentheses when it first appears Vaccines still protect against viral variants that are emerging in different parts of the world. However, manufacturers are working on ways to fine-tune their recipes in case the vaccine eventually needs to be updated.

The most worrisome variety today is the first to appear in South Africa. Moderna administers a vaccine specifically targeted at that variant, National Institute of Health For research.

U.S. regulators say it has been revamped vaccine Thousands of people won’t have to study for months. However, it needs to be tested with hundreds of people to see if their immune system responds as well as the updated shots as well as the original shots.

Relation: NIH to study the symptoms and effects of “long-distance” coronavirus

Relation: FDA Staff Announces Review of Johnson & Johnson Single-Dose COVID Vaccine

Modana also said that three doses of the original vaccine have begun testing whether additional immunity enhancements that can prevent mutations, even if they are not in perfect agreement, can be obtained.

In another announcement, Moderna also said it plans to produce 600-700 million COVID-19 vaccines worldwide this year. The company also said it is investing in new manufacturing capacity that could produce 1.4 billion doses in 2022.

COVID: New modeler vaccine for South African variants

Source link COVID: New modeler vaccine for South African variants

Related Articles

Back to top button